

**Table 1. Percentage point difference in vaccination coverage by age 19 months between adjacent survey years, among children with dates of birth included in both survey years, National Immunization Survey-Child, 2011–2017, United States**

NIS-Child Years Compared Month and Year of Birth	2011 vs. 2012		2012 vs. 2013		2013 vs. 2014		2014 vs. 2015		2015 vs. 2016		2016 vs. 2017	
	Jan 2009–May 2010		Jan 2010–May 2011		Jan 2011– May 2012		Jan 2012– May 2013		Jan 2013– May 2014		Jan 2014– May 2015	
Vaccine/Dose	%	(95% CI)	%	(95% CI)	%	(95% CI)	%	(95% CI)	%	(95% CI)	%	(95% CI)
<b>DTaP*</b>												
≥3 doses	-0.95	(±1.47)	-1.18	(±1.95)	-0.25	(±1.92)	-0.23	(±1.54)	<b>-2.12</b>	(±1.45)	0.33	(±1.96)
≥4 doses	-2.28	(±2.53)	-0.38	(±2.99)	2.25	(±3.02)	-2.57	(±2.89)	<b>-4.49</b>	(±2.73)	-0.52	(±3.04)
<b>Poliovirus (≥3 doses)</b>	-1.12	(±1.68)	-0.48	(±2.04)	0.03	(±2.02)	0.04	(±1.71)	<b>-3.23</b>	(±1.94)	-0.17	(±2.38)
<b>MMR (≥1 dose)</b>	-1.67	(±1.93)	0.66	(±2.19)	-0.93	(±2.08)	-0.34	(±2.29)	-1.15	(±1.91)	1.98	(±2.15)
<b>Hib†</b>												
Primary series	<b>-1.91</b>	(±1.61)	-0.05	(±1.80)	-1.56	(±1.98)	0.28	(±1.64)	<b>-2.19</b>	(±1.47)	-0.02	(±1.97)
Full series	-2.12	(±2.42)	0.61	(±2.96)	-0.10	(±2.96)	-1.53	(±2.78)	-2.60	(±2.56)	-0.49	(±3.03)
<b>HepB</b>												
≥3 doses	<b>-2.45</b>	(±1.88)	0.35	(±2.10)	-0.42	(±2.18)	-0.36	(±1.94)	<b>-3.39</b>	(±1.96)	1.55	(±2.01)
Birth dose <sup>§</sup>	-0.87	(±2.54)	2.38	(±2.76)	-2.18	(±3.09)	0.59	(±2.93)	-0.70	(±2.94)	2.19	(±3.14)
<b>Varicella (≥1 dose)</b>	-1.14	(±1.91)	1.28	(±2.24)	-1.96	(±2.08)	0.17	(±2.37)	-1.99	(±1.99)	-0.05	(±2.38)
<b>PCV</b>												
≥3 doses	<b>-1.75</b>	(±1.66)	-1.01	(±2.03)	-1.62	(±2.06)	-0.20	(±2.00)	<b>-2.81</b>	(±1.66)	-0.54	(±2.32)
≥4 doses	<b>-2.84</b>	(±2.38)	0.23	(±2.99)	-0.67	(±2.77)	-0.80	(±2.83)	<b>-4.74</b>	(±2.40)	0.54	(±2.85)
<b>HepA</b>												
≥1 dose	-0.83	(±2.46)	-0.17	(±2.78)	0.32	(±2.70)	0.30	(±2.85)	-2.11	(±2.34)	-1.05	(±2.64)
≥2 doses	0.90	(±2.16)	0.18	(±2.54)	1.10	(±2.55)	1.23	(±2.35)	-0.46	(±2.48)	1.35	(±2.85)
<b>Rotavirus¶</b>	<b>-2.94</b>	(±2.56)	1.61	(±2.92)	-2.56	(±3.12)	-0.90	(±2.98)	-0.80	(±2.66)	-1.87	(±2.93)
<b>Combined 7-vaccine series**</b>	<b>-3.75</b>	(±2.73)	-1.69	(±3.17)	2.15	(±3.17)	-0.71	(±3.14)	<b>-3.89</b>	(±2.91)	-1.10	(±3.21)

**Abbreviations:** CI = confidence interval; DTaP = diphtheria, tetanus toxoids, and acellular pertussis vaccine; HepA = hepatitis A vaccine; HepB = hepatitis B vaccine; Hib = *Haemophilus influenzae* type b conjugate vaccine; MMR = measles, mumps, and rubella vaccine; PCV = pneumococcal conjugate vaccine.

**Bolded** estimates of difference are statistically significant at  $p < 0.05$ , when the absolute value of estimate is larger than the half-width of the 95% CI.

\* Includes children who might have been vaccinated with diphtheria and tetanus toxoids vaccine or diphtheria, tetanus toxoids, and pertussis vaccine.

† Hib Primary series: receipt of ≥2 or ≥3 doses, depending on product type received. Full series: receipt of ≥3 or ≥4 doses, depending on product type received (primary series and booster dose).

§ One dose HepB administered between birth and age 3 days.

¶ Rotavirus vaccine includes ≥2 or ≥3 doses, depending on the product type received (≥2 doses for Rotarix [RV1] and ≥3 doses for RotaTeq [RV5]).

\*\* The combined 7-vaccine series (4:3:1:3\*:3:1:4) includes ≥4 doses of DTaP, ≥3 doses of poliovirus vaccine, ≥1 dose of measles-containing vaccine, the full series of Hib (≥3 or ≥4 doses, depending on product type of vaccine), ≥3 doses of HepB, ≥1 dose of varicella vaccine, and ≥4 doses of PCV.